On Tuesday 22 July, the European Commission approved the second health-related ‘important project of common European interest’ (IPCEI) to support innovation in medical devices.
The project, called ‘IPCEI Tech4Cure’, was jointly notified by five Member States (France, Hungary, Italy, Slovakia and Slovenia).
These Member States will provide up to €403 million in public funding, which should trigger a further €826 million in private investment.
Ten companies will be carrying out highly innovative research, development and initial industrial deployment projects. Six of these companies are SMEs.
‘Tech4Cure’ focuses primarily on the creation of innovative medical devices integrating advanced digital and AI solutions, which aim to further develop the concept of predictive, preventive and personalised medicine (3P medicine).
Predictive medicine uses data and analysis tools to anticipate an individual’s future health risks. Preventive medicine makes it possible to detect risk factors and medical conditions at an early stage, so that action can be taken in good time to prevent illness. Personalised medicine adapts treatments and care plans to the specific characteristics of each patient.
The 3Ps concept of medicine aims to improve patient outcomes, reduce healthcare costs, and increase the quality of life of EU citizens. ‘Tech4Cure’ will contribute to the EU’s updated industrial strategy by promoting industrial resilience and strengthening the single market. The ‘Tech4Cure’ project is scheduled for completion in 2036, with variable timetables depending on the projects and companies involved. 800 jobs are expected to be created.
Further details: https://aeur.eu/f/hyb (Original version in French by Lionel Changeur)